Thank you for donating!

You can donate using the following services.

News

  1. 15.07.19

    BOOK NOW: NPUK Interactive Workshop 2019

    This year the NPUK Interactive Workshop will take place on the 20th September at Wyboston Lakes, Bedfordshire - and will as ever be a fantastic opportunity for clinicians, health professionals and scientists working in the Niemann-Pick field to meet together under one roof...

    Read more
  2. 05.07.19

    BOOK NOW: NPUK Annual Family Conference 2019

    Our Annual Family Conference and Interactive Workshop on Niemann-Pick Diseases is the largest event in the NPUK calendar, bringing together affected individuals, families, health and research professionals under one roof...

    Read more
  3. 11.06.19

    Orphazyme to prepare for filing of arimoclomol in Europe for Niemann-Pick disease Type C (NPC)

    Orphazyme plans to meet with the US Food and Drug Administration (FDA) to discuss the pathway forward during the Summer and will provide an update after it has received written comments from the FDA...

    Read more
  4. 03.06.19

    CTD Holdings Closes $7.4 Million Private Placement

    CTD Holdings, Inc. (OTCQB: CTDH)("CTD" or the "Company"), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that it closed its previously announced private placement of securities with a group of institutional and accredited investors that included directors and officers of the Company.

    Read more
  5. 24.05.19

    CTD Announces Home-Based Dosing of First Patient in US Extension Protocol of Clinical Trial using Intravenous Administration of Trappsol® Cyclo™ for Niemann-Pick Disease Type C

    ALACHUA, FL – (Accesswire) – May 23, 2019 – CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced its first home-based infusion of its proprietary formulation of hydroxypropyl beta cyclodextrin, Trappsol® Cyclo™, in a formal clinical trial. The trial is “An Open-Label Extension Study of the Long-Term Safety and Efficacy of Intravenous Trappsol® Cyclo™ (HPBCD) in Patients with Niemann-Pick Disease Type C (NPC-1)” (ClinicalTrials.gov NCT03893071) in the United States.

    Read more